Hitoshi Honda1, Erik R Dubberke. 1. aDivision of Infectious Diseases, Department of Medicine, Tokyo Metropolitan Tama General Medical Center, Tokyo, Japan bDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Abstract
PURPOSE OF REVIEW: Clostridium difficile infection (CDI) is one of the most common healthcare-associated infections, and the threat associated with CDI continues to grow in all patient populations. There is increasing evidence that CDI has a substantial impact on the morbidity and mortality in solid organ transplant (SOT) recipients. Furthermore, new diagnostic and treatment options and strategies for CDI have emerged over the last decade. The purpose of this review is to provide a general understanding of CDI and its evidence-based diagnosis and management strategies, with a focus on SOT recipients. RECENT FINDINGS: The incidence and severity of CDI have significantly increased since the year 2000. Studies have identified novel risk factors for CDI, and a new epidemic strain, the NAP1/BI/027, has emerged. Despite the development of newer testing methods and approaches, including nucleic acid amplification tests and testing algorithms, the optimal method for diagnosing CDI is an area of controversy. New agents for treating CDI are being developed, and the use of fecal microbiota transplantation to treat recurrent CDI in SOT recipients is also evolving. SUMMARY: CDI is a significant problem for SOT recipients. Further studies on diagnostic and therapeutic strategies with a focus on SOT recipients are needed to further improve patient outcomes.
PURPOSE OF REVIEW: Clostridium difficileinfection (CDI) is one of the most common healthcare-associated infections, and the threat associated with CDI continues to grow in all patient populations. There is increasing evidence that CDI has a substantial impact on the morbidity and mortality in solid organ transplant (SOT) recipients. Furthermore, new diagnostic and treatment options and strategies for CDI have emerged over the last decade. The purpose of this review is to provide a general understanding of CDI and its evidence-based diagnosis and management strategies, with a focus on SOT recipients. RECENT FINDINGS: The incidence and severity of CDI have significantly increased since the year 2000. Studies have identified novel risk factors for CDI, and a new epidemic strain, the NAP1/BI/027, has emerged. Despite the development of newer testing methods and approaches, including nucleic acid amplification tests and testing algorithms, the optimal method for diagnosing CDI is an area of controversy. New agents for treating CDI are being developed, and the use of fecal microbiota transplantation to treat recurrent CDI in SOT recipients is also evolving. SUMMARY: CDI is a significant problem for SOT recipients. Further studies on diagnostic and therapeutic strategies with a focus on SOT recipients are needed to further improve patient outcomes.
Authors: E R Dubberke; K A Reske; M A Olsen; K Bommarito; A A Cleveland; F P Silveira; M G Schuster; C A Kauffman; R K Avery; P G Pappas; T M Chiller Journal: Transpl Infect Dis Date: 2018-03-06 Impact factor: 2.228
Authors: Suresh Paudel; Ioannis M Zacharioudakis; Fainareti N Zervou; Panayiotis D Ziakas; Eleftherios Mylonakis Journal: PLoS One Date: 2015-04-17 Impact factor: 3.240
Authors: Massimo Sartelli; Stefano Di Bella; Lynne V McFarland; Sahil Khanna; Luis Furuya-Kanamori; Nadir Abuzeid; Fikri M Abu-Zidan; Luca Ansaloni; Goran Augustin; Miklosh Bala; Offir Ben-Ishay; Walter L Biffl; Stephen M Brecher; Adrián Camacho-Ortiz; Miguel A Caínzos; Shirley Chan; Jill R Cherry-Bukowiec; Jesse Clanton; Federico Coccolini; Maria E Cocuz; Raul Coimbra; Francesco Cortese; Yunfeng Cui; Jacek Czepiel; Zaza Demetrashvili; Isidoro Di Carlo; Salomone Di Saverio; Irina M Dumitru; Christian Eckmann; Edward H Eiland; Joseph D Forrester; Gustavo P Fraga; Jean L Frossard; Donald E Fry; Rita Galeiras; Wagih Ghnnam; Carlos A Gomes; Ewen A Griffiths; Xavier Guirao; Mohamed H Ahmed; Torsten Herzog; Jae Il Kim; Tariq Iqbal; Arda Isik; Kamal M F Itani; Francesco M Labricciosa; Yeong Y Lee; Paul Juang; Aleksandar Karamarkovic; Peter K Kim; Yoram Kluger; Ari Leppaniemi; Varut Lohsiriwat; Gustavo M Machain; Sanjay Marwah; John E Mazuski; Gokhan Metan; Ernest E Moore; Frederick A Moore; Carlos A Ordoñez; Leonardo Pagani; Nicola Petrosillo; Francisco Portela; Kemal Rasa; Miran Rems; Boris E Sakakushev; Helmut Segovia-Lohse; Gabriele Sganga; Vishal G Shelat; Patrizia Spigaglia; Pierre Tattevin; Cristian Tranà; Libor Urbánek; Jan Ulrych; Pierluigi Viale; Gian L Baiocchi; Fausto Catena Journal: World J Emerg Surg Date: 2019-02-28 Impact factor: 5.469